BRIEF: De­ci­phera bags a $52M round to back its can­cer drug pipeline work

Waltham, MA-based De­ci­phera Ther­a­peu­tics has been care­ful­ly track­ing the ear­ly-stage progress it’s been mak­ing with its lead drug, a pan-KIT and PDGFR in­hibitor dubbed DCC-2618. And this morn­ing, the biotech an­nounced that it has banked a $52 mil­lion C round to keep fu­el­ing its grow­ing pipeline ef­forts.

Viking Glob­al In­vestors, Red­mile Group and Sphera Glob­al Health­care Fund led the round, joined by De­ci­phera’s ex­ist­ing in­vestors in­clud­ing New Leaf Ven­ture Part­ners.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.